Optimi Health Corp. IPO - What You Need to Know

Thinking about investing in Optimi Health Corp.? This Canadian company sits right in the middle of the growing psychedelic medicine market. Here is a plain-English guide to their upcoming U.S. public offering.

1. What does this company actually do?

Optimi is a licensed drug manufacturer based in British Columbia, Canada. They grow and produce medical-grade magic mushrooms (psilocybin) and synthetic MDMA.

It is important to know that they do not invent or develop new drugs themselves. Instead, they act as a supplier, selling these raw, high-quality ingredients to researchers, clinical trial operators, and prescribing doctors in countries like Australia, Canada, and Israel.

2. What is the big news with this IPO?

Optimi is launching a U.S. initial public offering (IPO) to list its shares on the Nasdaq under the ticker OPTH.

Here are the quick numbers you need to know:

• The Shares: They are offering 2,500,000 shares priced between US$6.00 and US$8.00 each.
• The Cash Raise: They expect to keep about US$12.2 million after paying fees (assuming a $7.00 midpoint). Before fees, they hope to bring in between US$15.0 million and US$20.0 million.

This move to a major U.S. exchange is designed to help them attract larger institutional investors and secure the capital they desperately need to keep running.

3. Why did the stock price suddenly change?

If you have been tracking Optimi, you might have noticed its shares recently traded for under $1.00. To meet Nasdaq's strict minimum price rules for listing, the company is executing a 1-for-30 reverse stock split right before the IPO.

Think of this like trading thirty $1 bills for one $30 bill. You do not actually have more money, but the price of a single share looks much higher. Every 30 shares you currently own will merge into one single share. This does not change the company's overall value or your percentage of ownership; it is simply a regulatory requirement to get onto the Nasdaq.

4. How do they make money?

Optimi is currently closing down its retail vitamin business to focus 100% of its energy on medical psychedelics. They essentially act as the "farmer and manufacturer." A good way to think about it is that they are selling high-quality shovels during a gold rush.

Right now, Optimi makes very little money from psychedelics because the market is so new. However, because they do not run expensive clinical trials themselves, they avoid the massive research costs that sink many biotech companies. Instead, they make money by selling raw ingredients directly to researchers and distributors.

5. What are the main risks?

While the opportunity is exciting, there are some very heavy risks to consider before buying in:

• A serious cash crunch: Optimi is burning through cash quickly. They lost C$3.7 million in fiscal year 2025, and another C$1.55 million (about US$1.13 million) in the following three months. They owe C$8.5 million in bills due this year but only have C$1.8 million in short-term assets—leaving a C$6.7 million cash shortage. Without this IPO money, they might go out of business or be forced to issue more shares, which would dilute your ownership.
• Strict U.S. limits: Even if the U.S. legalizes these drugs federally, government quotas strictly limit how much can be manufactured or imported. This places a hard ceiling on how much Optimi can actually sell in the U.S. market.
• Australia could change its mind: Australia is currently a key buyer. However, if patient data from their experimental prescribing program looks bad, the government could halt the program, instantly wiping out one of Optimi's major markets.
• They rely on other people's homework: Because Optimi does not run its own trials, they are at the mercy of their customers. If a customer fails a regulatory inspection or a trial gets shut down, Optimi's supply contracts get canceled, leaving them with unsold inventory.
• Product liability: Dealing with controlled substances carries high risk. Any contamination or incorrect dosing could lead to product recalls, lost manufacturing licenses, and massive lawsuits that could easily exceed their insurance coverage.

The Bottom Line

Optimi is a high-risk, high-reward bet. If you believe that the global medical psychedelic market is about to explode and you want a company that focuses on the supply side rather than expensive drug development, Optimi is worth keeping on your radar.

Just keep in mind their tight cash situation. Their survival heavily depends on a successful Nasdaq IPO to patch their current cash shortage. If you decide to invest, treat this as a highly speculative play and only invest money you are comfortable losing.